Stocklytics Platform
Asset logo for symbol SLN
Silence Therapeutics plc
SLN
$18.94arrow_drop_up1.55%$0.29
Asset logo for symbol SLN
SLN

$18.94

arrow_drop_up1.55%

Income Statement (SLN)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
EBIT-$17.25M-$3.35M-$15.02M-$10.65M-$11.11M
EBITDA-$17.13M-$3.23M-$14.90M-$10.52M-$10.99M
gross Profit-$2.04M$10.19M$753.00K$1.19M$6.27M
NET Income-$15.56M-$1.87M-$14.41M-$8.25M-$10.40M
total Revenue$598.00K$12.40M$2.09M$2.79M$9.10M

Balance Sheet (SLN)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
cash Equivalents-----
net Debt-$109.29M-$112.77M-$53.75M-$58.49M-$29.35M
stockholders Equity$112.50M$123.90M$17.05M$19.99M$12.25M
total Assets$188.63M$194.37M$93.82M$97.94M$92.71M
total Debt$184.00K$277.00K$272.00K$315.00K$364.00K
total Liabilities$76.12M$70.47M$76.77M$77.94M$80.45M

Cash Flow (SLN)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
financing Cash Flow$847.00K$105.56M$9.92M$12.03M$3.18M
free Cash Flow-$4.88M-$7.49M-$11.86M-$4.89M-$14.95M
investing Cash Flow-----$4.70M
operating Cash Flow-$4.81M-$7.49M-$11.86M-$4.87M-$14.95M

Silence Therapeutics plc (SLN) Financials

Silence Therapeutics plc (SLN) is a biotechnology company specializing in the development and commercialization of RNA-based therapeutics. The company's financials provide insight into its performance and financial health. The income statement shows the company's revenue and expenses over a specific period. It reveals Silence Therapeutics' net income from stockholders, gross profit, and total revenue. These figures reflect the company's profitability and revenue generation capabilities.
The balance sheet provides a snapshot of Silence Therapeutics' financial position at a specific point in time. It includes the company's total assets, total liabilities, and stockholders' equity. This information helps assess the company's financial stability and its ability to meet its financial obligations. Silence Therapeutics' cash equivalents and net debt also provide insights into its liquidity and leverage.
Cash flow statements detail the sources and uses of cash for Silence Therapeutics. The operating cash flow shows the cash generated from the company's core operations, while the investing cash flow and financing cash flow account for cash flows related to investments and financing activities. Silence Therapeutics' free cash flow is a measure of its ability to generate cash after accounting for capital expenditures.
As a publicly traded company, Silence Therapeutics' financials are crucial for investors and stakeholders to evaluate its financial performance and make informed decisions. These financial statements offer valuable insights into the company's revenue, expenses, profitability, liquidity, and financial health.
add Silence Therapeutics plc to watchlist

Keep an eye on Silence Therapeutics plc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media